^
Association details:
| Biomarker: | TET2 mutation + NRAS mutation |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
How to Treat Adult Acute Myeloid Leukemia: An Evolving Paradigm
Excerpt:
A 76-year-old woman presented...Molecular assays detected mutations in TET2 and NRAS. She was diagnosed with intermediate-risk AML....She was initiated on therapy with venetoclax plus azacitidine...achieving disease remission, improved symptoms, and life prolongation.
Secondary therapy:
azacitidine
DOI:
https://doi.org/10.1016/j.jaccao.2021.09.013
